ConAgra Stock To Go Ex-dividend Tomorrow (CAG)

NEW YORK ( TheStreet) -- The ex-dividend date for ConAgra Foods (NYSE: CAG) is tomorrow, October 27, 2011. Owners of shares as of market close today will be eligible for a dividend of 24 cents per share. At a price of $25.20 as of 9:30 a.m. ET, the dividend yield is 3.8%.

The average volume for ConAgra has been 5.2 million shares per day over the past 30 days. ConAgra has a market cap of $10.5 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 12.3% year to date as of the close of trading on Tuesday.

ConAgra Foods, Inc. operates as a food company primarily in North America. It operates in two segments, Consumer Foods and Commercial Foods. The Consumer Foods segment provides branded, private label, and customized food products, which are sold in various retail and foodservice channels. The company has a P/E ratio of 14.2, below the average food & beverage industry P/E ratio of 14.4 and below the S&P 500 P/E ratio of 17.7.
  • Practice your dividend trading strategies and win cash in our stock game.

TheStreet Ratings rates ConAgra as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full ConAgra Ratings Report.

See our dividend calendar or top-yielding stocks list.

null

More from Markets

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus